行情

CALA

CALA

Calithera
NASDAQ

实时行情|Nasdaq Last Sale

3.850
-0.120
-3.02%
盘后: 3.850 0 0.00% 16:00 09/19 EDT
开盘
3.990
昨收
3.970
最高
4.000
最低
3.780
成交量
37.12万
成交额
--
52周最高
6.90
52周最低
3.430
市值
2.07亿
市盈率(TTM)
-1.7339
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CALA 新闻

  • Calithera Biosciences, Inc. (NASDAQ:CALA): Is It Growing Too Fast?
  • Simply Wall St..14小时前
  • Edited Transcript of CALA earnings conference call or presentation 8-Aug-19 9:00pm GMT
  • Thomson Reuters StreetEvents.09/09 22:10
  • Calithera Biosciences (CALA) Investor Presentation - Slideshow
  • Seeking Alpha - Article.09/05 18:59
  • Calithera Biosciences Highlights Presentation Of New Data On 2 Oncology Programs At ESMO Congress
  • Benzinga.09/03 13:21

更多

所属板块

生物技术和医学研究
+0.01%
制药与医学研究
+0.41%

热门股票

名称
价格
涨跌幅

CALA 简况

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
展开

Webull提供Calithera Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。